focus -WSS

focus

author：comprehensive 2025-09-29 23:20:10 Page View：699

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?
Next article： Apple is now the first public company to be valued at $3 trillion

explore

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

EricRisberg/APTwodominantBlueCrossBlueShieldcompaniesinCaliforniaintentionallyunderreportedpremiumso

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Key House panel plots a new health care package

CommitteechairmanRep.JasonSmith(R-Mo.)speakswithrankingmemberRep.RichardNeal(D-Mass.).DrewAngerer/Ge